Arvaya Healthcare Rights Issue (13 Nov 2026)
Arvaya Healthcare Ltd announces Q2 FY2026-27 financials, rights issue, and acquisition
Arvaya Healthcare · Commercial Services & Supplies
Key highlights
- Approved proposed rights issue of partly paid-up equity shares worth ₹210 crore on July 11, 2026.
- Completed acquisition of 100% equity shares of Sushodha Institute of Gastroenterology Pvt Ltd on Nov 1, 2026, via share swap allotting 38,71,854 shares.
- Reported standalone revenue from operations of ₹40.1 crore and consolidated revenue of ₹40.81 crore for quarter ended Sept 30, 2026.
Original filing
Unaudited Standalone And Consolidated Financial Results For The Quarter Ended 30Th September 2026
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Aerospace & Defense
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Arvaya Healthcare
- Acquisition / mergerArvaya Healthcare Ltd reports Q2 & H1 FY 2026-27 unaudited financial results and approves rights issue
- Fundraise / allotmentNotableArvaya Healthcare Limited approves Draft Letter of Offer for ₹205.8 crore Rights Issue
- Fundraise / allotmentNotableArvaya Healthcare Limited revises Rights Issue committee authorisation details
- Fundraise / allotmentNotableArvaya Healthcare Limited proposes Rights Issue of Equity Shares up to ₹210 Cr
- Acquisition / mergerNotableArvaya Healthcare Limited completes acquisition of 100% equity of SIGPL
Other financial results filings this fortnight
- Financial resultsJindal PhotoJindal Photo Ltd files unaudited financial results and reports voluntary delisting
- Financial resultsGSP Crop ScienceGSP Crop Science Limited announces financial results and corporate updates for H1 FY 2026-27
- Financial resultsA-One Steels IndiaA-One Steels India Limited announces unaudited Q2 and half-year financial results for 2026
- Financial resultsNatural CapsulesNatural Capsules Limited approves Q2 FY27 financials and preferential allotment
- Financial resultsCapitalNumbers InfotechCapitalNumbers Infotech Limited announces unaudited H1 FY2026 financial results
- Financial resultsGlobal Vectra HelicorpGlobal Vectra Helicorp Limited files unaudited results for Q2 & H1 ended Sept 2026
Potential multibaggers · Q2 FY27
Potential multibaggers in Commercial Services & Supplies
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.